文章核心观点 公司推出了一套数字和数据解决方案,旨在提高临床试验效率、减少数据延迟并简化调查员现场工作流程 [1][2] 关键要点总结 公司概况 - 公司是全球领先的创新和综合实验室服务提供商 [6] - 公司拥有超过67,000名员工,为全球约100个国家的客户提供服务,在2023年FDA批准的新药和治疗产品中提供了84%的支持,并为全球患者进行了超过6亿次检测 [6] 产品介绍 - 公司推出了"Labcorp Global Trial Connect"套件,这是一套面向中央实验室的解决方案,旨在加快临床试验的进度,重点关注调查员现场的体验 [1][2] - 该套件包括以下功能: - 现场启用资源 - 帮助识别新的研究机会,增强患者获取和招募,提高临床试验的多样性 [2] - 供应准备支持 - 提高研究启动效率,减少试验延迟,减少供应和试剂盒浪费 [3] - 现场工作流程促进 - 帮助整合样本采集和跟踪数据,为现场和赞助商提供可见性和可操作的分析,通过电子申请功能减少错误、查询、暂停和数据修订 [4] - 研究管理和调查员支持 - 加快研究启动并保持研究势头,提供全天候现场支持以及按需工具和培训 [5]

文章核心观点 - 公司宣布推出新的精准肿瘤基因组分析服务Labcorp Tissue Complete,并将在日内瓦和上海的实验室提供该服务,以支持全球临床试验 [1][2][3] - 公司通过整合OmniSeq INSIGHT液体活检综合基因组分析,进一步扩大了在固体肿瘤液体活检综合基因组分析领域的领导地位 [4] 公司概况 - Labcorp是一家全球领先的创新和综合实验室服务公司 [5] - 公司拥有超过67,000名员工,为约100个国家的客户提供服务,在2023年FDA批准的新药和治疗产品中提供了84%的支持,并为全球患者进行了超过6亿次检测 [5] 新服务亮点 - Labcorp Tissue Complete是一项用于研究和调查用途的综合基因组分析服务,采用FDA批准和CE认证的PGDx elio™ tissue complete assay技术 [2] - 该服务利用Labcorp的全球实验室网络,标准化多中心生物标志物导向的患者检测,减少了由于不同化学试剂、工作流程和数据分析管道造成的差异 [2] - 该服务将通过日内瓦和上海的自有实验室提供,以支持全球临床试验,简化患者进入肿瘤临床试验的渠道,扩大患者群体,并提高Labcorp全球网络的物流效率 [3] - 公司还将OmniSeq INSIGHT液体活检综合基因组分析纳入其综合基因组分析服务组合,使其能够从血液和组织样本中提供一致的基因组变异、肿瘤突变负荷和微卫星不稳定性检测,支持制药公司的探索性和纵向生物制药研究 [4]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style Score ...

Laboratory Corporation of America Holdings or Labcorp (LH) recently introduced a screening test for preeclampsia in the first trimester, which will be done between weeks 11 and 14 of pregnancy to estimate the risk of preeclampsia before 34 weeks of pregnancy. This is the only test of its kind accessible in the United States and applicable to all expectant mothers, even those with first-time pregnancies or those at low to average risk of preeclampsia. With the latest launch, LK is now the only laboratory tha ...

Laboratory Corporation of America Holdings (LH) , or Labcorp, is well-poised to grow in the coming quarters, led by collaborations with leading pharmaceutical and biotechnology companies.  Labcorp also remains active on the acquisition front, maintaining a solid business development pipeline.However, adverse currency fluctuations are a concerning for the company.   In the past year, this Zacks Rank #3 (Hold) stock has gained 6.3% compared with a 4.7% rise of the industry and a 27.8% increase of the S&P 500 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number 1-11353 LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact name of registrant as specified in its charter) Delaware 13-3757370 (St ...

Assay expands company's leadership in precision medicine and cell and gene therapy BURLINGTON, N.C., April 29, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the U.S. Food and Drug Administration (FDA) has approved its nAbCyte™ Anti-AAVRh74var HB-FE Assay, a companion diagnostic (CDx) to determine patient eligibility for treatment with BEQVEZ™ (fidanacogene elaparvovec-dzkt), Pfizer's recently FDA-approved hemophilia B gene thera ...

财务数据和关键指标变化 - 第一季度收入总计32亿美元,同比增长4.6% [29] - 诊断实验室业务收入25亿美元,同比增长4.1% [37] - 生物医药实验室服务业务收入7.11亿美元,同比增长7.5% [40] - 整体企业调整后营业利润率为14.3%,同比下降0.4个百分点 [30] - 诊断实验室业务调整后营业利润率为16.9%,同比下降1.6个百分点 [39] - 生物医药实验室服务业务调整后营业利润率为14.1%,同比增长3个百分点 [41] 各条业务线数据和关键指标变化 - 诊断实验室业务量同比增长3.4%,其中基础业务量增长4.9% [38] - 诊断实验室价格/组合同比增长0.6%,基础业务价格/组合同比增长1.7% [38] - 生物医药实验室服务业务中,中央实验室收入同比增长13%,早期开发业务收入同比下降4% [40] 各个市场数据和关键指标变化 - 公司未具体披露各个市场的数据和关键指标变化 [无] 公司战略和发展方向及行业竞争 - 公司完成收购Invitae部分资产,将加强公司在肿瘤和罕见疾病领域的专业检测能力 [9][10][11] - 公司继续通过收购和战略合作扩大在医疗系统和区域实验室的合作伙伴关系 [15][16] - 公司持续推出新的检测产品,如阿尔茨海默病诊断和监测的血液生物标志物检测、早期肠癌复发风险检测等 [17][18][19] - 公司在神经退行性疾病、肿瘤等领域持续保持技术和创新领先地位 [17][18][19] 管理层对经营环境和未来前景的评论 - 公司第一季度业务保持强劲增长势头,有望在2024年全年保持良好表现 [12][14] - 公司预计诊断和生物医药实验室服务业务的全年利润率将同比提升 [14][41] - 公司对生物医药实验室服务业务中早期开发业务的恢复持谨慎态度,但有信心中央实验室业务的强劲表现可以抵消其影响 [40][41] 问答环节重要的提问和回答 问题1 **Jack Meehan 提问** 询问收购Invitae资产的战略意义以及与公司现有肿瘤业务的协同 [50] **Adam Schechter 回答** Invitae在遗传性肿瘤和罕见疾病领域有很强的实力,能够很好地补充公司现有的业务,加强公司在这些领域的领导地位 [51] 问题2 **Erin Wright 提问** 询问诊断实验室业务指引中收购贡献和基础业务增长的比重 [57] **Glenn Eisenberg 回答** 收购交易约占诊断实验室业务指引上调的一半,另一半来自基础业务需求的增长 [59] 问题3 **Patrick Donnelly 提问** 询问生物医药实验室服务业务中早期开发业务的情况 [65] **Adam Schechter 和 Glenn Eisenberg 回答** 尽管早期开发业务的订单量和取消率仍高于正常水平,但公司有信心随着时间推移这一情况会得到改善,同时中央实验室业务的强劲表现可以抵消早期开发业务的影响 [66][67]

Laboratory Corporation of America Holdings (LH) , or Labcorp, reported adjusted earnings per share (EPS) of $3.68 in the first quarter of 2024, up 6.4% from the year-ago quarter’s figure.The adjusted figure excludes the impact of certain amortization expenses and restructuring charges, among others. The bottom line also beat the Zacks Consensus Estimate by 6.4%.On a GAAP basis, EPS in the first quarter was $2.69, up 12.6% from the last year’s comparable period.RevenuesRevenues in the quarter under review ro ...

FOR IMMEDIATE RELEASE Contact: Christin O'Donnell (investors) – 336-436-5076 Investor@Labcorp.com Kimbrel Arculeo (media) – 336-436-8263 Media@Labcorp.com Labcorp Announces 2024 First Quarter Results Updates Full-Year Guidance • Results from Continuing Operations for first quarter 2024 versus last year: ◦ Revenue: $3.18 billion versus $3.04 billion or up 4.6% | Base Business grew 6.7% ◦ Diluted EPS: $2.69 versus $2.34 ◦ Adjusted EPS: $3.68 versus $3.46 • Full-Year 2024 Guidance: Raised midpoint and narrowed ...